ALDH2 Determines Strain‑Specific Lipid Peroxidation Adduct Burden and Senescence via Mitochondrial Protein Modification

Hypothesis

Variability in lipid peroxidation adduct accumulation across mouse strains and tissues stems from differences in mitochondrial aldehyde dehydrogenase 2 (ALDH2) activity, which determines the clearance of reactive aldehydes before they adduct mitochondrial proteins. Strains with high ALDH2 efficiently detoxify 4‑hydroxynonenal (HNE) and malondialdehyde (MDA), limiting adduct formation on Complex I, II and ATP synthase subunits, whereas low ALDH2 activity permits adduct accumulation, respiratory dysfunction and senescence via p53/SIRT1‑independent pathways.

Mechanistic Rationale

ALDH2 oxidizes reactive aldehydes to their corresponding acids, reducing the pool of HNE/MDA available for Michael addition on cysteine and lysine residues of mitochondrial proteins Complex I subunit NDUFS1, Protein adduct formation. When ALDH2 activity is low, aldehydes persist, increasing adduct formation on electron transport chain subunits, which impairs complex activity and elevates mitochondrial ROS. This ROS burst can oxidize cardiolipin and promote release of cytochrome c, activating the NLRP3 inflammasome independent of p53 Mitochondria‑targeted antioxidants SkQ1. Moreover, adduct‑laden ATP synthase subunits diminish proton coupling, causing a mild bioenergetic shift that activates AMPK and suppresses SIRT1 deacetylase activity, reinforcing a senescence‑associated secretory phenotype (SASP) Open questions on adducts and senescence.

Testable Predictions

1. Mouse strains exhibiting low basal ALDH2 activity (e.g., DBA/2) will show higher HNE/MDA adduct accumulation on mitochondrial proteins after oxidative challenge, despite their reported resistance to age‑related increase Strain‑specific adduct patterns.
2. Pharmacological activation of ALDH2 with Alda‑1 will reduce adduct levels on NDUFS1, SDHA/SDHB and ATP5A/B subunits and delay senescence markers (p16^INK4a, SASP cytokines) in C57BL/6 mice subjected to paraquat‑induced lipid peroxidation.
3. Liver‑specific ALDH2 knockout in C57BL/6 mice will recapitulate the adduct accumulation pattern seen in old kidney, leading to early onset of mitochondrial respiration defects and inflammasome activation, even in young animals.
4. Adducted mitochondrial proteins isolated from ALDH2‑deficient tissue will trigger NLRP3 inflammasome activation in macrophage cultures, an effect blocked by adduct‑scavenging hydralazine.

Experimental Approach

• Measure ALDH2 activity in mitochondrial extracts from skeletal muscle, kidney and liver of C57BL/6 and DBA/2 mice at 3, 12 and 24 months using a NAD^+-dependent acetaldehyde oxidation assay.
• Quantify HNE/MDA adducts on Complex I, II and ATP synthase subunits by immunoprecipitation followed with anti‑HNE/MDA western blot Complex I subunit NDUFS1, Protein adduct formation.
• Treat cohorts with Alda‑1 (10 mg/kg/day) or vehicle for 8 weeks; assess adduct burden, oxygen consumption rate (Seahorse), senescence‑associated β‑galactosidase, and serum IL‑6/TNF‑α.
• Generate liver‑specific ALDH2 floxed mice crossed with Alb‑Cre; confirm knockout by qPCR and activity assay.
• Isolate mitochondria from knockout and control livers, incubate with RAW 264.7 macrophages transfected with NLRP3‑luciferase reporter; measure luciferase release and caspase‑1 cleavage.

Potential Outcomes and Falsification

If ALDH2 activity does not correlate with adduct burden across strains/tissues, or if Alda‑1 fails to lower adducts and senescence despite increased enzyme activity, the hypothesis would be falsified. Conversely, a consistent inverse relationship between ALDH2 activity, adduct levels, and senescence markers would support the model and suggest a therapeutic avenue independent of caloric restriction or mitochondrial‑targeted antioxidants.